Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
- PMID: 31863534
- PMCID: PMC7154653
- DOI: 10.1111/dth.13190
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Abstract
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type-2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type-2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has the potential to inhibit both IL-4 and IL-13. We propose IL-4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
Keywords: blistering diseases; bullous pemphigoid; dupilumab; mucous membrane pemphigoid; pemphigus vulgaris.
© 2019 The Authors. Dermatologic Therapy published by Wiley Periodicals, Inc.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
New immunomodulating drugs in autoimmune blistering diseases.Dermatol Clin. 2001 Oct;19(4):637-48, viii. doi: 10.1016/s0733-8635(05)70305-3. Dermatol Clin. 2001. PMID: 11705351 Review.
-
Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid.Acta Derm Venereol. 2004;84(5):381-4. doi: 10.1080/00015550410031825. Acta Derm Venereol. 2004. PMID: 15370705
-
Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica.Clin Dermatol. 2016 Mar-Apr;34(2):205-13. doi: 10.1016/j.clindermatol.2015.11.006. Epub 2015 Dec 19. Clin Dermatol. 2016. PMID: 26903186 Review.
-
A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis.Front Immunol. 2022 Feb 9;13:825796. doi: 10.3389/fimmu.2022.825796. eCollection 2022. Front Immunol. 2022. PMID: 35222408 Free PMC article.
-
A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry.Front Immunol. 2019 Sep 20;10:2219. doi: 10.3389/fimmu.2019.02219. eCollection 2019. Front Immunol. 2019. PMID: 31608053 Free PMC article.
Cited by
-
Study of cytokine-induced immunity in bullous pemphigoid: recent developments.Ann Med. 2023;55(2):2280991. doi: 10.1080/07853890.2023.2280991. Epub 2023 Dec 18. Ann Med. 2023. PMID: 38109924 Free PMC article. Review.
-
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?J Clin Med. 2022 Jun 12;11(12):3367. doi: 10.3390/jcm11123367. J Clin Med. 2022. PMID: 35743438 Free PMC article. Review.
-
SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma.JCI Insight. 2022 Nov 8;7(21):e160977. doi: 10.1172/jci.insight.160977. JCI Insight. 2022. PMID: 36136606 Free PMC article.
-
Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review.JAAD Int. 2023 Aug 31;13:134-136. doi: 10.1016/j.jdin.2023.08.015. eCollection 2023 Dec. JAAD Int. 2023. PMID: 37786789 Free PMC article. No abstract available.
-
Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.Immun Inflamm Dis. 2023 Jul;11(7):e924. doi: 10.1002/iid3.924. Immun Inflamm Dis. 2023. PMID: 37506153 Free PMC article.
References
-
- Aoudjehane, L. , Pissaia, A., Jr. , Scatton, O. , Podevin, P. , Massault, P. P. , Chouzenoux, S. , … Conti, F. (2008). Interleukin‐4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the stat‐6 pathway. Laboratory Investigation, 88, 973–985. - PubMed
-
- Bailey, J. R. , Bland, P. W. , Tarlton, J. F. , Peters, I. , Moorghen, M. , Sylvester, P. A. , … Whiting, C. V. (2012). IL‐13 promotes collagen accumulation in Crohn's disease fibrosis by down‐regulation of fibroblast MMP synthesis: A role for innate lymphoid cells? PLoS One, 7, e52332. - PMC - PubMed
-
- Bellini, A. , Marini, M. A. , Bianchetti, L. , Barczyk, M. , Schmidt, M. , & Mattoli, S. (2012). Interleukin (IL)‐4, IL‐13, and IL‐17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunology, 5, 140–149. - PubMed
-
- Belperio, J. A. , Dy, M. , Burdick, M. D. , Xue, Y. Y. , Li, K. , Elias, J. A. , & Keane, M. P. (2002). Interaction of IL‐13 and C10 in the pathogenesis of bleomycin‐induced pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 27, 419–427. - PubMed
-
- Bernard, P. , & Antonicelli, F. (2017). Bullous pemphigoid: A review of its diagnosis, associations and treatment. American Journal of Clinical Dermatology, 18, 513–528. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical